News
We send the latest information from SMC Laboratories.
SMC attend Digital partnering events 【Bio Asia-Taiwan 2023】!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering™ in Bio Asia-Taiwan 2023 from July 26th to 30th. We would love to have the opportunity to meet with you virtually and introduce ourselves and our preclinical models, so please join us! If you would like to discuss specific…
【Publication Archive】 Study focusing on iron metabolism and mitophagy for the treatment of NASH and HCC published in EMBO Rep.
Please take a look at published study focusing on intracellular iron metabolism and mitophagy as therapeutic targets for hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). Title: Iron loss triggers mitophagy through induction of mitochondrial ferritin ► Full text LINK [Hara Y et al., EMBO Rep. 2020] In this paper, it has been shown that…
Announcement of webinar 【Chronic kidney disease model ~Instructions on how to Tubular injury score】
Today, we are excited to invite you to join our Webinar that will be taking place on July 20th (JST) from 9:30 AM. In this webinar, we will focus on preclinical study for chronic kidney disease (CKD). In particular, we will introduce how to evaluate renal injury based on pathological findings, which is one…
Webinar Archive
I am writing you today to share with you about our Webinar. We occasionally organize webinars focusing on NASH and IPF, which are our primary areas of interest. We have previously conducted webinars on various topics, and the recordings are available in our webinar archive. ▶ Webinar archive [ Link ] The topics…
89bio Inc. and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s 89bio Inc. (CA/ISR)will present results of a study using STAM™ mice at poster presentation at EASL Congress 2023 in Vienna, Austria, June 21-24, 2023. Presentation details are as follows: Abstract Title: Pegozafermin inhibits NASH-induced hepatocellular carcinoma in the STAM mouse model Abstract Number: SAT-243 Format: Poster Presenting Author: Maya…
AprilBio Co., Ltd., and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s AprilBio Co., Ltd., (KOR) will present results of a study using STAM™ mice at poster presentation at EASL Congress 2023 in Vienna, Austria, June 21-24, 2023. Presentation details are as follows: Abstract Title: APB-R3, a novel long-acting IL-18 binding protein, inhibits IL-18 activity, and thereby ameliorates NASH progress with…
Our article was published in Nature Brand magazine (Biopharma Dealmakers)!
It's about the concept of metabolic-associated fatty liver disease (MAFLD) and how we work with it, which could have important implications for drug development in non-alcoholic fatty liver disease (NAFLD). As we know, the lack of appropriate mouse models of the disease for NAFLD is a barrier to drug development and is thought…
New Service: In Vitro Assay for Fibrosis Evaluation
We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation. By launching this service, we now offer a cost-effective and efficient way to conduct preliminary studies and screen compounds for potential fibrotic effects, saving valuable time and resources in your drug development journey. This not only speeds…
Introducing our new pulmonary fibrosis model: Silica-induced pulmonary fibrosis model
Today, we are pleased to announce that we have expanded our preclinical model lineup by including the “Silica-induced pulmonary fibrosis model”. Pulmonary fibrosis in silica models occurs early and is maintained long term. Hence, this model is one of the most beneficial model mice for therapeutic study for pulmonary fibrosis. In general, human pulmonary…
Study published in Pharmacol Res Perspect. on the efficacy of the inhibitor of serine palmitoyltransferase (SPT) in STAM™
SMC is proud to announce that Chugai Pharmaceutical Co., Ltd. (JPN) has published the results of their study using our pre-clinical services with the STAM™ mouse in Pharmacol Res Perspect. Title Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non‐alcoholic steatohepatitis (NASH) (Hada et…